When Drug Reviewers Leave The FDA, They Often Work For Pharma
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
Sydney Lupkin
Sydney Lupkin was a data correspondent for KFF Health News until November 2019.
Showing 41 - 44 of 44
-
-
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
-
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
-
Study Bodes Well For Biosimilars But Highlights Need For More Research
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: